SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q1 Trading Update

18 Apr 2019 07:00

RNS Number : 5559W
Rentokil Initial PLC
18 April 2019
Β 

Β 

RENTOKIL INITIAL PLC (RTO)

FIRST QUARTER TRADING UPDATE

18 April 2019

Β 

(Β£m)

Β 

Q1 2019

Growth

Β 

Β 

AER

AER

CER

Ongoing Revenue1

Β 

603.6

10.6%

8.9%

Revenue

Β 

607.4

10.3%

8.6%

Β 

Overview

Trading has started well across our businesses in Q1 with Ongoing Revenue1 increasing by 8.9%, of which 4.0% was Organic Revenue2 growth (Q1 2018: 3.2%, FY 2018: 3.7%) and 4.9% was from acquisitions.

Ongoing Revenue in Pest Control grew by 12.0%, 5.0% Organic (Q1 2018: 4.7%), with good performances being delivered across both Growth and Emerging markets, which rose by 12.1% and 11.5% respectively. Hygiene has made a very positive start to the year, with Ongoing Revenue growth of 7.2% and Organic Revenue growth of 4.3% (Q1 2018: 1.8%). Ongoing Revenue in our Protect & Enhance markets was in line with Q1 2018.

M&A

​We signed eight acquisitions in Q1, four in Pest Control (primarily in North America and Latin America) and four in Hygiene, with combined annualised revenues of c. Β£29m in the year prior to purchase. We are encouraged about our prospects for further M&A this year and our pipeline of value-enhancing opportunities is strong. Our guidance for M&A spend in 2019 remains in the range of Β£200m to Β£250m. Β 

Pension Scheme and Funding

In December 2018 the Company reached agreement for a bulk annuity insurance 'buy-in' for its UK Defined Benefit Pension scheme ("the Scheme") in contemplation of a full 'buy-out' which is expected to complete in early 2020. Good progress towards buy-out is being made andΒ we now anticipate a pre-tax cash surplus of c. Β£40m will be returned to the Company on completion.

Ahead of the refinancing of our €500m bond maturing in September this year, we are intending to hold a non-deal, bond investor education roadshow in London, France, Germany, the Netherlands, Nordics and Asia. We will release further details in due course.

​Commenting on today's announcement Andy Ransom, Chief Executive, said:

"We have had a good start to 2019 and I'm pleased with our performance in the first three months of this year. I am confident of another year of successful growth for the Company, in line with market expectations."

Β 

Enquiries:

Β 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Β 

Β 

Β 

Β 

Media:

Malcolm Padley

Rentokil Initial plc

07788 978199

Β 

Β 

Β 

Β 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

Β 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

Β 

AER - actual exchange rates; CER - constant 2018 exchange rates

Β 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
TSTZMGMDRNMGLZM
Date   Source Headline
11th Jan 20084:08 pmRNSHolding(s) in Company
10th Jan 200810:19 amRNSHolding(s) in Company
27th Dec 200710:11 amRNSDisposal
21st Dec 20079:57 amRNSHolding(s) in Company
20th Dec 200712:18 pmRNSDirector/PDMR Shareholding
18th Dec 20074:37 pmRNSDirector/PDMR Shareholding
14th Dec 20074:48 pmRNSHolding(s) in Company
14th Dec 200712:39 pmRNSDirector/PDMR Shareholding
13th Dec 20074:19 pmRNSDirector/PDMR Shareholding
13th Dec 20077:01 amRNSTrading Statement
12th Dec 200710:28 amRNSHolding(s) in Company
8th Nov 20077:01 amRNS3rd Quarter Results
19th Oct 200712:27 pmRNSAnnual Calendar 2008
17th Oct 20072:47 pmRNSHolding(s) in Company
8th Oct 20074:16 pmRNSDirector/PDMR Shareholding
1st Oct 20074:20 pmRNSTotal Voting Rights
28th Sep 20074:43 pmRNSDirector/PDMR Shareholding
25th Sep 200710:09 amRNSHolding(s) in Company
23rd Aug 20077:00 amRNSInterim Results
8th Aug 20072:57 pmRNSHolding(s) in Company
31st Jul 20079:50 amRNSTotal Voting Rights
30th Jul 200710:55 amRNSHolding(s) in Company
30th Jul 20077:01 amRNSAcquisition
19th Jul 20077:00 amRNSDirectorate Change
17th Jul 20077:00 amRNSAcquisition
9th Jul 200712:38 pmRNSHolding(s) in Company
2nd Jul 20074:27 pmRNSDisposal
29th Jun 200712:04 pmRNSHolding(s) in Company
27th Jun 20074:16 pmRNSRegulatory Inquiry Outcome
21st Jun 200710:47 amRNSHolding(s) in Company
11th Jun 200710:41 amRNSHolding(s) in Company
31st May 20074:27 pmRNSTotal Voting Rights
24th May 200710:01 amRNSHolding(s) in Company
3rd May 20075:50 pmRNSAGM Statement
2nd May 20077:01 amRNSTrading Update
1st May 20073:43 pmRNSTotal Voting Rights
24th Apr 20071:21 pmRNSCorporate Responsibility Rev
20th Apr 20078:00 amRNSDoc re. Company News
20th Apr 20078:00 amRNSAcquisition
19th Apr 200711:39 amRNSAnnual Information Update
30th Mar 20072:41 pmRNSAnnual Report and Accounts
30th Mar 20077:04 amRNSDisposal
15th Mar 20077:02 amRNSRentokil Tropical Plants
13th Mar 20079:04 amRNSHolding(s) in Company
7th Mar 20074:52 pmRNSDirector/PDMR Shareholding
7th Mar 200712:25 pmRNSStatement re: OFT clearance
28th Feb 20075:00 pmRNSDirector/PDMR Shareholding
22nd Feb 20077:02 amRNSFinal Results
21st Feb 20075:09 pmRNSHolding(s) in Company
31st Jan 20075:40 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.